David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.
A new technique developed by scientists in Japan to reverse balding using hairfollicle cell transplants, and the discussion around the effectiveness of this approach compared to other treatments such as Minoxidil, finasteride, RU58841, Replicel, and Hairclone.
Dutasteride 0.5 mg significantly reduces both scalp and hairfollicle DHT, with a greater reduction in hairfollicle DHT. The discussion questions which reduction is more important for androgenetic alopecia and diffuse thinning.
Pelage is developing a topical hairfollicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
How Finasteride and Dutasteride help reduce hair loss by reducing the amount of DHT in scalp areas, as well as discussing factors such as sensitivity to DHT, 5α-reductase expression in different parts of the hairfollicle, and scalp tension.